TheraPanacea
- Company typePrivate
- Founded2017
- HeadquartersParis, France
- Headcount51–100
- GTM typeB2B
- OfferingSoftware
TheraPanacea firmographics
Firmographics- Name
- TheraPanacea
- Legal name
- TheraPanacea (Société Anonyme)
- Website
- https://therapanacea.eu
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
TheraPanacea industry classification
Industry- Product category
- Radiation Oncology AI Software
- NAICS
- Software Publishers (5132), Irradiation Apparatus Manufacturing (334517)
- SIC
- Services-Prepackaged Software (7372), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Radiology AI, CAD & Advanced Visualization Software (HLAHABAJ)
- akta.pro secondary industries
- Medical Imaging AI (HDAAAEAH), Vendor Neutral Archive (VNA) & Enterprise Imaging Repositories (HLACALAC)
Keywords
Where TheraPanacea is headquartered
LocationHeadquarters
- HQ city
- Paris
- HQ country
- France
- HQ region
- Europe
Offices2 records
Markets served
TheraPanacea business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Revenue model
- ART-Plan™ Software Licenses: AI-powered radiotherapy software deployed to healthcare providers, generating recurring license revenue. Software is CE-marked and FDA/TGA cleared, deployed across 300+ centers in Europe and 230+ clinical instances worldwide.
- Pharmaceutical AI/Biomarker Services: ART-Omics platform offered to pharmaceutical companies for biomarker discovery, patient selection for clinical trials, and drug development optimization. Biogen collaboration provides up to $56M (including $15M convertible debt and $41M milestones).
- Strategic Partnerships & Milestone Payments: R&D collaboration agreements with pharma companies (Biogen) generating milestone-based payments contingent on achievement of research and development milestones.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise license for radiotherapy departments |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
TheraPanacea product offering
Product offeringCore offering
TheraPanacea develops and sells AI-powered medical device software for radiotherapy treatment planning and oncology. Its flagship ART-Plan™ platform automates contouring, image fusion, pseudo-CT generation, adaptive radiotherapy decision support, and treatment plan generation for cancer centers and radiotherapy departments. The company also offers ART-Omics™, an AI-driven radiomics platform for biomarker discovery used by pharmaceutical companies in drug development and clinical trial patient stratification.
Product overview
TheraPanacea offers a comprehensive AI-powered oncology platform centered on ART-Plan™/ART-Plan+™ for radiotherapy optimization. The core platform integrates multiple modules: Annotate (automated contouring), SmartFuse (image fusion), MR-Box (MR-only workflows), AdaptBox (adaptive radiotherapy decisions), SmartPlan (automated treatment planning), and TumorBox (brain tumor segmentation). The company also provides ART-Omics™ as a separate AI-powered biomarker discovery platform for pharmaceutical companies. The portfolio is complemented by Neuro Solutions for Alzheimer's Disease and Multiple Sclerosis applications. All products are designed for clinical use in radiation therapy settings, with CE-mark, FDA clearance, and TGA clearance for the main ART-Plan platform.
Differentiator
Problem solved
Functional benefit
Brands
- ART-Plan™: AI-powered radiotherapy software platform for adaptive cancer treatment planning, contouring, and treatment optimization. Includes modules for auto-contouring, image fusion, pseudo-CT generation, and adaptive radiotherapy decision support.
- ART-Omics™
Products and services
- ART-Plan™ AI-powered radiotherapy software platform that optimizes every step of the treatment process from preparation to follow-up for radiation oncologists, medical physicists, and dosimetrists at cancer centers and hospitals.
- ART-Plan+™ Enhanced ART-Plan medical device edition offering automatic treatment plan generation for supported prescriptions and anatomies, synthetic-CT generation, and improved processing precision for clinical radiotherapy teams.
- Annotate Automated contouring solution providing zero-click, expert-level delineation of 250+ organs at risk and lymph nodes in up to 3 minutes for radiation oncology teams, delivering up to 95% time saving in contouring.
- SmartFuse AI-powered image fusion module providing high-precision rigid and elastic alignment between scans from different imaging modalities in a single click for radiotherapy planning workflows.
- MR-Box MR-only workflow solution generating pseudo-CT from MR images for supported anatomies, including brain proton therapy, eliminating the need for a separate planning CT scan.
- AdaptBox AI-driven adaptive radiotherapy decision support module that generates synthetic CTs from Cone-Beam CTs, automates organ segmentation, and calculates dose distribution to determine when replanning is needed during a treatment course.
- SmartPlan AI-powered automated treatment planning module that generates clinically acceptable radiotherapy treatment plans for prostate, breast, and head and neck workflows within the ART-Plan platform.
- TumorBox AI-powered brain tumor auto-segmentation module delivering precision segmentation of brain tumors, including glioblastoma, with DSC scores up to 0.88 within the ART-Plan platform.
- ART-Omics™ AI-powered plug-n-play radiomics platform combining unsupervised biomarker discovery with clinical domain knowledge for advanced diagnosis, prognosis, and disease monitoring in neurosciences and oncology, marketed to pharmaceutical companies for biomarker discovery and clinical trial patient stratification.
Quantifiable outcome
- Up to 93% of time saved in contouring
- +7 more outcomes
Companies that use TheraPanacea
Customer profileNamed customers5 records
Segments2 records
Ideal customer profiles2 records
TheraPanacea technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
AI capability7 records
Feature8 records
TheraPanacea partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered flagship and core.
- BiogenflagshipBiogen and TheraPanacea collaboration in neuroscience to develop AI/ML solutions for personalized medicine. Biogen invests up to $15M in convertible debt plus up to $41M in milestone payments. Biogen gains exclusive rights to TheraPanacea technology in neuroscience. Collaboration aims to improve disease understanding and enable more personalized clinical trial design through medical imaging and AI analysis.
- Gustave RoussycoreLeading French cancer center, one of the most prominent clinical collaborators for AI in radiation oncology research. Joint development of multiple studies and validation of AI tools.
- Institut CuriecorePrestigious French cancer research and treatment center. Clinical collaboration partner for AI in radiation oncology research.
- Centre Léon BérardcoreLeading French comprehensive cancer center. Clinical collaborator with published testimonials on 60% time savings using Annotate and standardization benefits.
- CHU NîmescoreFrench university hospital center participating in clinical research collaborations for AI in radiation oncology.
- Penn MedicinecoreLeading US academic medical center. International collaboration partner for AI in radiation oncology research.
- CentraleSupélec / University of Paris-SaclaycoreAcademic spin-off from CentraleSupélec, University of Paris-Saclay. Provides access to academic patents and research expertise. CEO Nikos Paragios is Distinguished Professor in Applied Mathematics at CentraleSupélec.
Scale indicators6 records
Recent moves7 records
Expansion highlights6 records
TheraPanacea competitors and assessment
Company assessmentDirect peers
- RaySearch Laboratories: Swedish developer of RayStation treatment planning system and RayCare oncology information system, a direct competitor in AI-augmented radiotherapy planning and a validated integration partner for TheraPanacea's ART-Plan+ in plan generation.
- Radformation: US-based developer of AI-driven automation tools for radiation oncology workflows (auto-contouring, planning, QA), directly overlapping with TheraPanacea's ART-Plan modules targeting radiation oncology departments.
- MVision AI: Finnish provider of AI-based auto-contouring solutions for radiotherapy, a focused direct competitor in the same AI contouring product category sold to European cancer centers.
- Limbus AI: Developer of AI auto-contouring software (Limbus Contour) for radiotherapy, competing head-to-head with TheraPanacea's Annotate module for OAR and lymph node delineation in clinical workflows.
- Mirada Medical: UK-based medical imaging AI company specializing in oncology image analysis, deformable registration, and treatment planning automation — directly comparable to TheraPanacea's SmartFuse and broader imaging AI stack.
- Aidence: European AI radiology company (acquired by RadNet) focused on AI for lung nodule detection and oncology imaging, overlapping with TheraPanacea's clinical AI imaging capabilities for cancer care.
Broad incumbents
- Elekta: Global leader in radiation therapy equipment (LINACs) and oncology software (Mosaiq, Monaco), whose installed base shapes demand for TheraPanacea's contouring/planning software and competes broadly in AI-enabled radiotherapy.
- Varian Medical Systems (Siemens Healthineers): Acquired by Siemens Healthineers, Varian is the dominant radiation oncology platform provider (Eclipse/ARIA) and a validated TPS integration partner for TheraPanacea, but also a competitor embedding AI in its own portfolio.
- Philips HealthSuite / Philips Radiation Oncology: Diversified health technology incumbent offering imaging, treatment planning, and increasingly AI-driven oncology workflow tools, providing both competitive pressure and partnership context for AI radiotherapy vendors.
Emerging players
- Annalise.ai: Australia-based AI company offering a broad radiology AI platform including chest X-ray and CT triage/detection models, adjacent to TheraPanacea's medical imaging AI capabilities for oncology workflows.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights6 records
Customer concentration
TheraPanacea social profiles
Digital presenceTheraPanacea compliance and trust
Trust signalCompliance4 records
TheraPanacea financial estimates
Financial estimateRevenue estimate
Valuation estimate
TheraPanacea leadership team
Management profileNumber of profiles
Profiles3 records
TheraPanacea funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
TheraPanacea M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about TheraPanacea
What does TheraPanacea do?
TheraPanacea develops and sells AI-powered medical device software for radiotherapy treatment planning and oncology. Its flagship ART-Plan™ platform automates contouring, image fusion, pseudo-CT generation, adaptive radiotherapy decision support, and treatment plan generation for cancer centers and radiotherapy departments. The company also offers ART-Omics™, an AI-driven radiomics platform for biomarker discovery used by pharmaceutical companies in drug development and clinical trial patient stratification.
Is TheraPanacea a public or private company?
TheraPanacea is a private company. It is classified as venture growth investor backed and is currently operating.
When was TheraPanacea founded?
TheraPanacea was founded in 2017. It employs 51 to 100 people.
Where is TheraPanacea based?
TheraPanacea is headquartered in Paris, France, in the Europe region.
How does TheraPanacea make money?
Three revenue lines are on record. ART-Plan™ Software Licenses are the primary driver. The others are pharmaceutical AI/Biomarker Services and strategic Partnerships & Milestone Payments.
Who are TheraPanacea's main competitors?
Direct peers on record are RaySearch Laboratories, Radformation, MVision AI, Limbus AI, Mirada Medical and Aidence. Broad incumbents are Elekta, Varian Medical Systems (Siemens Healthineers) and Philips HealthSuite / Philips Radiation Oncology. Annalise.ai is listed as an emerging player.
Does TheraPanacea have an API?
No public API is recorded for TheraPanacea.
What industry is TheraPanacea in?
TheraPanacea's product category is Radiation Oncology AI Software. Its primary akta.pro industry code is HLAHABAJ, Radiology AI, CAD & Advanced Visualization Software, with a secondary code of HDAAAEAH, Medical Imaging AI. Its NAICS code is 5132 and its SIC code is 7372.